Remdesivir was the first drug approved by the FDA for treating the SARS-CoV-2 virus. It is indicated for treatment of COVID-19 disease in hospitalized adults and children aged 12 years and older who weigh at least 40 kg. The broad-spectrum antiviral is a nucleotide analog prodrug.
Dosage:
- Day 1 loading dose: 200 mg IV infused over 30-120 min, THEN
- Day 2 to 5: 100 mg IV qDay
Adverse Effects:
- >10% eGFR decreased* (18%)
- Decreased CrCl* (calculated by Cockcroft-Gault) (10-18%)
- Creatinine increased* (5-15%)
- Hemoglobin decreased* (6-15%)
- Glucose increased* (11-12%)
- Lymphocytes decreased* (11%)
- 1-10%
- Prothrombin time increased (9%)
- ALT increased* (3-8%)
- AST increased* (6-7%)
- Nausea (3-5%)
- Bilirubin increased* (2%)
- Hypersensitivity reactions (<2%)
- Generalized seizure (<2%)
- Rash (<2%)
Storage:
Lyophilized powder
- Unopened vial: Store <30ºC (<86ºF)
- Reconstituted vial: Use reconstituted product immediately to prepare diluted solution
- Diluted solution: Stable for 24 hr at 20-25ºC (68-77ºF) or 48 hr refrigerated at temperature 2-8ºC (36-46ºF)
Solution for injection:
- Unopened vial: Refrigerate at 2-8ºC (36-46ºF); may store at room temperature up to 12 hr before dilution.
- Diluted solution: Stable for 24 hr at 20-25ºC (68-77ºF) or 48 hr refrigerated at temperature 2-8ºC (36-46ºF)